Editorial correspondence
Kiss Peptide welcomes correspondence on the research record: a citation quoted inaccurately, a regulatory reference that has been superseded, or a peer-reviewed study on kisspeptin or PT-141 that belongs on the references page. A correction that sharpens accuracy is the most useful message this casebook can receive.
The most actionable notes name three things: the page they refer to, the exact passage in question, and a supporting citation — a DOI or PubMed ID wherever possible. That lets a proposed change be checked against the source quickly.
Notes about the FDA prescribing information for bremelanotide are especially welcome when the label has been updated, since regulatory documents change and this casebook aims to reflect current approval status.
Editorial mailbox: editors@kisspeptide.com
What this desk cannot do
Kiss Peptide is a casebook, not a clinic or a vendor, so it cannot:
- Weigh in on human use of any peptide covered here.
- Name a dose, schedule, or route for any individual.
- Diagnose anything, or say whether a given finding applies to a given person.
- Sell, source, or help anyone locate a compound from any supplier.
- Judge whether bremelanotide is appropriate for someone's medical situation — that belongs with a licensed prescriber.
- Field requests from athletes about using these compounds under the WADA framework for non-approved peptides.
Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Replies to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.